Clinical Trial Update: A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating QL1706 in combination with a nine-valent HPV vaccine as first-line treatment for persistent, recurrent, or metastatic cer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Nine-valent HPV vaccine (HPV vaccine, nine-valent)
• QL1706

Snippet

Sponsor: Northern Jiangsu People's Hospital | Conditions: Cervical Cancer Stage IVB | Phase 2 | Status: NOT_YET_RECRUITING